Whether to drop a secondary endpoint that will dominate the AdCom

Situation

FDA Response and Labeling work in a biologics company planning a biosimilar pathway now turns on to drop a secondary because an FAERS cluster in a demographic the trials under-enrolled put biosimilar analytical similarity report in play. Labeling negotiator should say what biosimilar analytical similarity report proves.

Decision

Labeling negotiator in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Biosimilar analytical similarity report reads as Proceed under protocol once an FAERS cluster in a demographic the trials under-enrolled is lined up to the same Pharma & Life Sciences population.
• Biosimilar analytical similarity report is closer to Pause the pathway after an FAERS cluster in a demographic the trials under-enrolled; Proceed under protocol would over-claim this FDA Response and Labeling extract.
• Escalate safety review is still live in biosimilar analytical similarity report for labeling negotiator in a biologics company planning a biosimilar pathway.
• Biosimilar analytical similarity report is missing the fact labeling negotiator needs after an FAERS cluster in a demographic the trials under-enrolled; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary.
• Check whether biosimilar analytical similarity report supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in a biologics company planning a biosimilar pathway.
• For this Pharma & Life Sciences FDA Response and Labeling file, read biosimilar analytical similarity report against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to drop a secondary for labeling negotiator.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled). The follow-on FDA Response and Labeling action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.